Accessibility StatementSkip Navigation Of the 12 patients treated with escalating doses of REQORSA and standard doses of osimertinib, all of whom had progressed on osimertinib containing regimens, three patients had experienced prolonged time to progression, including one with continuing partial response. Specifically, one patient at the 0.06 mg/kg dose level, previously treated with carboplatin, pemetrexed and osimertinib, had a partial remission by investigator evaluation, and as of the data from April 20 ...

AUSTIN, Texas, Nov. 19, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company has added Gabrail Cancer Center in Canton, Ohio, as a new clinical trial site for the Acclaim-1 and Acclaim-3 clinical trials studying its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), in lung cancer. In addition, the Company expect ...

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Olema Pharmaceuticals, Inc. (OLMA) has seen a substantial increase of 213%, trading at $26.68 - Diginex Limited (DGNX) is up 12%, currently priced at $15.25 - Gorilla Technology Group Inc. (GRRR) has risen by 11%, trading at $14.05 - Amer Sports, Inc. (AS) is up 9%, priced at $33.47 - Click Holdings Limited (CLIK) has increased by 9%, trading at $7.38 - Beamr Imaging Ltd. (BMR) is up 9%, currently at $2.14 - James Hardie Industries plc (JHX) has risen by 8%, trading at $18.22 - Arvinas, Inc. (ARVN) is up 8%, priced at $12.00 - Axalta Coating Systems Ltd. (AXTA) has increased by 7%, trading at $30.28 - Genprex, Inc. (GNPX) is up 6%, currently at $4.31 [3] Premarket Losers - LifeMD, Inc. (LFMD) has decreased by 22%, trading at $3.65 - Alpha Technology Group Limited (ATGL) is down 21%, currently priced at $17.00 - Intellinetics, Inc. (INLX) has fallen by 19%, trading at $7.25 - Energizer Holdings, Inc. (ENR) is down 16%, priced at $20.00 - Invivyd, Inc. (IVVD) has decreased by 14%, currently at $2.42 - BellRing Brands, Inc. (BRBR) is down 12%, trading at $22.30 - Sadot Group Inc. (SDOT) has fallen by 9%, currently priced at $3.99 - CEVA, Inc. (CEVA) is down 8%, trading at $21.60 - Helmerich & Payne, Inc. (HP) has decreased by 7%, currently at $25.44 - Opendoor Technologies Inc. (OPEN) is down 5%, trading at $7.39 [4]

or Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 Delaware 90-0772347 3300 Bee Cave Road, #650-227, Austin, TX 78746 (Address of principal executive offices) (Zip Code) (512) 537-7997 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ t ...

Core Points - Genprex, Inc. has announced a registered direct offering of 377,780 shares of common stock at a price of $9.00 per share, with potential additional gross proceeds of up to $6.6 million from short-term warrants [1][2] - The offering is expected to close around October 29, 2025, subject to customary closing conditions [1] - H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering [2] Financial Details - The gross proceeds from the offering are anticipated to be approximately $3.4 million before deducting fees and expenses [2] - The short-term warrants will allow the purchase of up to 755,560 shares at an exercise price of $8.75 per share, which will be immediately exercisable [1][2] Regulatory Information - The shares are being offered under a "shelf" registration statement that was declared effective by the SEC on June 9, 2023 [3] - The unregistered warrants and underlying shares are being offered in a private placement and have not been registered under the Securities Act [4] Company Overview - Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes [6] - The company's lead product candidate, Reqorsa® Gene Therapy, is being evaluated in clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) [7] - Genprex's diabetes gene therapy approach aims to transform pancreatic alpha cells into functional beta-like cells to produce insulin [7]

Core Insights - Genprex, Inc. announced positive preclinical data for Reqorsa® Gene Therapy targeting ALK-EML4 positive non-small cell lung cancer (NSCLC) [1][3][4] - The data was presented at the 2025 AACR-NCI-EORTC International Conference, highlighting the potential of Reqorsa in combination with Alectinib to improve treatment outcomes [2][3] Company Overview - Genprex is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, utilizing innovative technologies to deliver disease-fighting genes [7][9] - The company's lead product, Reqorsa, is designed to deliver the TUSC2 gene specifically to cancer cells while minimizing effects on normal tissues [6][9] Research Findings - Preclinical studies demonstrated that Reqorsa can upregulate the tumor suppressor gene TUSC2, inducing apoptosis in ALK+ NSCLC cells, including those resistant to Alectinib [4][6] - The combination of Reqorsa and Alectinib resulted in longer survival rates in mouse models compared to control groups, supporting the potential for clinical trials in ALK-positive lung cancer [3][4] Clinical Development - Reqorsa is currently being evaluated in two clinical trials for NSCLC and small cell lung cancer (SCLC), both of which have received Fast Track Designation from the FDA [9] - The SCLC program has also received Orphan Drug Designation from the FDA, indicating its potential to address unmet medical needs [9]

Core Points - Genprex, Inc. has announced a registered direct offering of 243,622 shares of common stock at a price of $11.21 per share, with expected gross proceeds of approximately $2.7 million [1][2] - The company will also issue unregistered short-term warrants to purchase up to 487,244 shares at an exercise price of $11.00 per share, potentially adding up to $5.4 million in gross proceeds if fully exercised [1][2] - The offering is expected to close around October 24, 2025, pending customary closing conditions [1] Financial Details - The gross proceeds from the offering are estimated at $2.7 million before deducting fees and expenses [2] - If the short-term warrants are fully exercised, the additional gross proceeds could reach approximately $5.4 million [2] Regulatory Information - The shares are being offered under a "shelf" registration statement declared effective by the SEC on June 9, 2023 [3] - The unregistered warrants and underlying shares are offered in a private placement and have not been registered under the Securities Act [4] Company Overview - Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes [6] - The company's lead product candidate, Reqorsa® Gene Therapy, is in clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) [7] - Genprex's diabetes gene therapy approach aims to transform pancreatic alpha cells into functional beta-like cells to produce insulin [7]

Core Insights - Genprex, Inc. announced positive preclinical data for its Reqorsa® Gene Therapy, indicating its potential effectiveness in treating ALK-EML4 positive non-small cell lung cancer (NSCLC) [1][2] - The therapy demonstrated a 79% tumor shrinkage rate, outperforming alectinib, which showed a 60% reduction [7] Company Overview - Genprex is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, utilizing its Oncoprex® Delivery System to administer gene therapies [10] - The lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is currently being evaluated in clinical trials for NSCLC and small cell lung cancer (SCLC) [10] Research Findings - Preclinical studies showed that Reqorsa can induce apoptosis in ALK+ NSCLC cell lines and patient-derived organoids, leading to significant tumor reduction [6][8] - The combination of Reqorsa and alectinib resulted in a 23% improved outcome compared to alectinib alone, suggesting its potential as a companion drug for advanced disease [7] Upcoming Presentations - Positive preclinical data will be presented at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics, highlighting the efficacy of Reqorsa in NSCLC [1][3]

Market Movements - Australian Oilseeds Holdings Limited Warrant (NASDAQ:COOTW) surged by 494.86% to $0.18 with a trading volume of 3,759,243, while its ordinary shares (COOT) increased by 244.87% to $3.32 with a trading volume of 167,502,947, despite facing a Nasdaq notification regarding non-compliance with the minimum stockholders' equity requirement of $10 million [1][4] - Genprex, Inc. (NASDAQ:GNPX) saw a 193.90% increase in its stock price to $0.74 with a trading volume of 825,729,912, driven by anticipation of promising preclinical data on its Reqorsa® Gene Therapy, which targets ALK-EML4 positive translocated non-small cell lung cancer [1][4] - Omeros Corporation (NASDAQ:OMER) experienced a 170.73% increase in its stock price to $11.1 with a trading volume of 107,994,321, following a significant licensing agreement with Novo Nordisk valued at up to $2.1 billion, granting exclusive global rights to develop and commercialize Omeros' MASP-3 inhibitor [1][4] Investor Interest - Bonk, Inc. Warrant (BNKKW) experienced a 125.16% price increase to $0.17 with a volume of 127,897, indicating investor interest in the company's prospects [2] - The reasons behind these surges include positive clinical trial results, strategic corporate developments, and broader market trends favoring these sectors [2] - The market environment reflects significant investor interest across various sectors, including biotechnology and consumer defensive, with analysts closely monitoring these companies for further developments [3]

Core Insights - Genprex, Inc. (NASDAQ: GNPX) has made the Nasdaq top gainers list due to positive preclinical data regarding its lead drug candidate, Reqorsa® Gene Therapy [4][5] - The stock price increased by 204.75%, trading at $0.7695 with a morning high of $1.10 and a trading volume exceeding 643 million shares [4] Company Developments - Genprex's research collaborators are set to present positive preclinical data at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 22-26, 2025, in Boston [5] - The preclinical data pertains to the treatment of ALK-EML4 positive non-small cell lung cancer (NSCLC) using Reqorsa® Gene Therapy [5][6] Management Commentary - Ryan Confer, President and CEO of Genprex, expressed enthusiasm about the presentation of positive preclinical data, highlighting the potential of Reqorsa to induce apoptosis in ALK positive lung cancer, particularly affecting young, non-smoking individuals [6]